PFE - Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

2024-06-03 14:32:19 ET

Summary

• Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price.
• The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100.
• The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
• With a deep RNAi drug pipeline, Alnylam appears undervalued for long-term investors even if HELIOS-B fails, but there is definitely a significant "win big / lose big" risk in the near term.

Investors are likely only four to five weeks away from getting their first look at clinical data from Alnylam Pharmaceuticals, Inc. (ALNY) that will likely have a significant influence on the share price of this leading RNA interference (or RNAi) biotechnology company. If the company’s HELIOS-B study is a clear success and drives a differentiated efficacy profile relative to competitors, a share price in the high-$200’s is a definite possibility, while a failure could drive a drop toward $100 and a frustrating wait for other pipeline assets to mature....

For further details see: